To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
ExonHit Licenses Merck Rights to RNA Splicing Microarray Patent
ExonHit Therapeutics S.A. has announced that Merck & Co., Inc. has been granted a non-exclusive license to rights for research only under Patent US 6,881,571.
It is not anticipated that the revenues received by ExonHit from Merck under this agreement will exceed US$150,000 per year.
Patent US 6,881,571, entitled "Qualitative Differential Screening", was granted on April 19, 2005 and has claims directed to microarrays optimized for the monitoring of RNA splicing events.
